Original Article | Published:

Ebp1 sumoylation, regulated by TLS/FUS E3 ligase, is required for its anti-proliferative activity

Oncogene volume 29, pages 10171030 (18 February 2010) | Download Citation

Abstract

Ebp1, an ErbB3 receptor-binding protein, inhibits cell proliferation and acts as a putative tumor suppressor. Ebp1 translocates into the nucleus and functions as a transcription co-repressor for E2F-1. Here, we show that Ebp1 p42 isoform can be sumoylated on both K93 and K298 residues, which mediate its nuclear translocation and are required for its anti-proliferative activity. We find that translocation in liposarcoma (TLS)/FUS, an RNA-binding nuclear protein that is involved in pre-mRNA processing and nucleocytoplasmic shuttling, has Sumo1 E3 ligase activity for Ebp1 p42. Ebp1 directly binds TLS/FUS, which is regulated by genotoxic stress-triggered phosphorylation on Ebp1. Ebp1 sumoylation facilitates its nucleolar distribution and protein stability. Overexpression of TLS enhances Ebp1 sumoylation, whereas depletion of TLS abolishes Ebp1 sumoylation. Moreover, unsumoylated Ebp1 mutants fail to suppress E2F-1-regulated transcription, resulting in loss of its anti-proliferation activity. Hence, TLS-mediated sumoylation is required for Ebp1 transcriptional repressive activity.

Introduction

Ebp1, a ubiquitously expressed protein, localizes in both the nucleus and the cytoplasm and binds ErbB3 receptor in human breast cancer cells (Yoo et al., 2000). Ebp1 is the human homolog of a previously identified cell–cycle-regulated mouse protein p38-2G4 (Radomski and Jost, 1995). The treatment of serum-starved AU565 breast cancer cells by the ErbB3/4 ligand heregulin (HRG) results in dissociation of Ebp1 from ErbB3 and translocation from the cytoplasm into the nucleus (Yoo et al., 2000). EBP1 overexpression inhibits proliferation of human fibroblasts, and this effect is linked to its nucleolar localization (Squatrito et al., 2004). Northern blotting analysis shows two transcripts with1.7 kb being the major one and 2.2 kb the minor one (Nakagawa et al., 1997). These observations are consistent with the report that two Ebp1 mRNAs occur in several normal human organs (Yoo et al., 2000). Recently, we report that the PA2G4 gene encodes two Ebp1 isoforms, p48 and p42, which differentially regulate PC12 cell survival and differentiation (Ahn et al., 2006; Liu et al., 2006). P48 is 54 amino acids longer than p42 at its N-terminus. The longer form p48 localizes in both the cytoplasm and the nucleolus and suppresses apoptosis, whereas the shorter form p42 predominantly resides in the cytoplasm and promotes cell differentiation (Liu et al., 2006). Ebp1 is phosphorylated on serine 360 (S360) by protein kinase Cδ, which strongly stimulates Ebp1 p48 to bind Akt and suppresses apoptosis (Ahn et al., 2006). Ebp1 p42 specifically associates with nucleophosmin (NPM)/B23 on epidermal growth factor stimulation, whereas p48 constantly binds NPM/B23. NPM/B23 regulates cell proliferation and survival through p42 and p48, respectively (Okada et al., 2007). Ebp1 also binds tumor suppressor retinoblastoma protein (Rb), leading to inhibition of the E2F1-regulated transcription (Xia et al., 2001; Zhang et al., 2003). Ebp1 contains an autonomous C-terminal transcriptional repression domain that binds histone deacetylase 2 (Zhang et al., 2005). It strongly suppresses both androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells and salivary adenoid carcinoma cell metastasis in mice (Zhang et al., 2005; Yu et al., 2007). Thus, Ebp1 p42 acts as a tumor suppressor by repressing E2F-1 and androgen receptor-mediated transcription.

TLS (translocation in liposarcoma) was initially identified as the N-terminus of TLS-CHOP (CCAAT/enhancer binding protein (C/EBP) homologous protein), a fusion oncoprotein that is expressed as a consequence of the t(12;16) translocation, which is implicated in human myxoid and round cell liposarcomas (Crozat et al., 1993; Rabbitts et al., 1993). TLS or the related EWS (Ewing's sarcoma) gene is also fused to a panel of unrelated transcription factors through chromosomal translocation in some of the human sarcomas and leukemias. The merged oncoproteins contain an N-terminal domain from TLS or EWS (Sanchez-Garcia and Rabbitts, 1994). The C-terminal domain of TLS is replaced by the DNA-binding domain from the corresponding transcription factor. The N-terminal domain in the fusion oncoproteins has a critical role in transformation (Zinszner et al., 1994; Kuroda et al., 1997). TLS possesses an SYGQ-rich region in the N-terminus, an RNA recognition motif, a C2/C2 zinc-finger motif and at least one RGG repeat region in the C-terminus (Morohoshi et al., 1998). Therefore, TLS binds RNA in vitro and in vivo (Crozat et al., 1993; Prasad et al., 1994; Zinszner et al., 1997b); it is expressed at high levels in hematopoietic and non-hematopoietic tissues (Aman et al., 1996), and localized primarily in the nucleus, where it may be involved in pre-mRNA processing and nucleocytoplasmic shuttling, as well as in the regulation of basal transcription (Ron, 1997; Zinszner et al., 1997a).

In this study, we show that p42 but not p48 is sumoylated, which is regulated by protein kinase Cδ-mediated phosphorylation. P42 sumoylation provokes its nucleolar translocation. TLS/Fus acts as a Sumo E3 ligase for Ebp1 p42. TLS directly binds to both Ubc9 and Ebp1 and promotes Ebp1 sumoylation. Disruption of Ebp1 sumoylation abolishes its anti-proliferative activity.

Results

Ebp1 p42 but not p48 isoform can be sumoylated

Tumor suppressors including NPM/B23 and p53 are usually regulated by sumoylation. To investigate whether both Ebp1 isoforms, p42 and p48, can be sumoylated, we used stably transfected F293 cells, which express tetracycline (Tet)-inducible His-Sumo1 or His-Sumo3. F293 cells were transfected with green fluorescent protein (GFP) alone, GFP-p42 and p48, and the Tet-induced-His-Sumo modified proteins were pulled down with the Nickel affinity column. Immunoblotting analysis showed that Ebp1 p42 but not p48 was robustly sumoylated by both Sumo1 and Sumo3 (Figure 1a, top panel). Co-transfection with FLAG-Sumo1 also verified that p42 but not p48 was selectively sumoylated (Figure 1b). To examine whether Ebp1 can directly associate with SUMO1, we co-transfected GFP-Sumo1 into HEK293 cells with various glutathione S-transferase (GST)-tagged Ebp1 fragments. GST-pull-down assays showed that p48 did not bind to Sumo1, and deletion of its N-terminal 22 amino acids (a.a.; 23–394) elicited evident association (Figure 1c, lower left panel, lanes 2 and 3), whereas the fragments (a.a. 292–360) and (a.a. 23–136) robustly interacted with GFP-Sumo1 (lanes 1 and 4). Thus, the N-terminal 22 amino acids in p48 inhibit its association with Sumo1. Presumably, it explains why p48 cannot be sumoylated.

Figure 1
Figure 1

Ebp1 p42 but not p48 is sumoylated. (a) His-Sumo1 or His-Sumo3 cells were transfected with each 10 μg of green fluorescent protein (GFP), GFP-p42 or GFP-p48. Total cell lysates (500 μg) were pulled down with nickel (Ni2+) resin. The beads were washed extensively and subjected to immunoblotting (IB) with anti-GFP antibody. (b) Ebp1 p42 but not p48 can be sumoylated. Glutathione S-transferase (GST)-tagged p42 and p48 were co-transfected with FLAG-Sumo1 into HEK293 cells. Sumoylated proteins were immunoprecipitated with anti-FLAG antibody and analysed by IB with anti-GST-horseradish peroxide (HRP) (right panel). (c) Truncation of the N-terminus of p48 elicits the association between Ebp1 and Sumo. Various GST-Ebp1 fragments were co-transfected with GFP-Sumo1 into HEK293 cells. GST-recombinant proteins were pulled down with glutathione beads and analysed by IB with anti-GFP antibody. Diagram of different Ebp1 constructs (upper panel). C-terminal a.a. 292–360 and N-terminal 23–136 fragments strongly bound GFP-Sumo1 (lower left panels). Verification of transfected GST fusion proteins (lower right panel). (d) DNA damage agents enhance p42 sumoylation. FLAG-Sumo1 was co-transfected with 2 μg of GFP-p42 into HEK293 cells, followed by treatment with various DNA damage agents for 4 h. P42 was immunoprecipitated with anti-GFP and analysed by anti-sumo antibody (top panel). p53 phosphorylation by DNA damage agents was verified (bottom panel). (e) Heregulin triggers Ebp1 sumoylation in AU565 breast cancer cells. MCF7 or AU565 cells were treated with heregulin (10 ng/ml) for 30 min and then subjected to immunoprecipitation with anti-Ebp1 antibody and immunoblotted with anti-Sumo1 antibody (left top panel). Actinomycin D (10 nM) but not DMSO provoked Ebp1 sumoylation in AU565 cells (bottom panels).

Genotoxic stress frequently elicits protein sumoylation (Watts, 2006; Huen and Chen, 2008). To assess whether DNA damage reagents can provoke Ebp1 sumoylation, we used a few DNA damage agents (actinomycin D, adriamycin and VP16), which have been shown to stabilize covalent DNA intermediates of the topoisomerase I (for example, VP16) or to inhibit RNA polymerases (for example, actinomycin D). Compared with DMSO control, 4 h treatment with actinomycin D, adriamycin and VP16 markedly elevated the sumoylation of Ebp1 p42 (Figure 1d, top panel). DNA damage induces phosphorylation of p53 at Ser15 and Ser20 and leads to a reduced interaction between p53 and its negative regulator, the oncoprotein MDM2 (Shieh et al., 1997; Meek, 1998). Immunoblotting analysis showed that these three agents provoked robust p53 phosphorylation (Figure 1d, bottom panel).

Ebp1 binds ErbB3 in breast cancer cells, and translocates into the nucleus on HRG stimulation (Yoo et al., 2000). To examine whether endogenous Ebp1 is also sumoylated in breast cancer cells, we treated MCF7 and AU565 cells with HRG and immunoprecipitated Ebp1 with Ebp1 antibody, which recognizes both p42 and p48. Ebp1, which was upregulated on HRG treatment, was sumoylated in AU565 but not MCF7 cells (Figure 1e, left top panel). As control, sumoylated Ebp1 was selectively immunoprecipitated by Ebp1 antibody but not control IgG (Figure 1e, right panels). To explore whether DNA damage agents also provoke a similar effect, we treated AU565 cells with actinomycin D for various time points. Reverse immunoprecipitation with anti-Sumo1 showed evident endogenous Ebp1 sumoylation by actinomycin but not DMSO when compared with control IgG (Figure 1e, bottom panels). Together, these observations support that Ebp1 p42 is sumoylated on growth factor stimulation or genotoxic stress.

TLS/FUS is a Sumo E3 ligase for Ebp1

To search for Sumo E3 ligases that regulate p42 sumoylation, we transfected mammalian-expressing GST and GST-p42 constructs into His-Sumo1 and His-Sumo3 cells. The transfected proteins were pulled down with glutathione beads, and the co-precipitated proteins were eluted and resolved on SDS–PAGE (polyacrylamide gel electrophoresis), followed by silver staining. Similar protein binding profiles were observed for both His-Sumo1 and His-Sumo3 samples, and prominent protein bands were subjected to proteomic analysis (Figure 2a, left panel). As expected, we identified NPM/B23, which confirmed our previous finding that Ebp1 associates with B23 in the nucleolus (Okada et al., 2007). In addition, we found numerous ribonucleoproteins, verifying a previous report (Squatrito et al., 2004). Among these binding partners, we also identified a zinc-finger containing protein TLS, which is a nucleocytoplasmic shuttling protein that binds RNA and mediates pre-mRNA processing (Ron, 1997; Zinszner et al., 1997a). Nucleolar proteins, including hBRE1 and TLS, were confirmed by immunoblotting to associate with Ebp1 (Figure 2a, right panel). To investigate whether TLS regulates p42 sumoylation in intact cells, we co-transfected FLAG-Sumo1 and TLS and Ubc9 into HEK293 cells with GFP-p42. P42 was prominently sumoylated when either E2 (Ubc9) or E3 (TLS) enzyme was overexpressed. The maximal effect occurred when both E2 and E3 enzymes were highly expressed (Figure 2b), suggesting that TLS can facilitate p42 sumoylation in intact cells. An in vitro sumoylation assay further supported this observation. Both the N-terminus of TLS (a.a. 1–290) and full length of TLS but not its C-terminus (a.a. 357–525) robustly stimulated Ebp1 sumoylation (Figure 2c). To ascertain that TLS is required for p42 sumoylation, we knocked down endogenous TLS with its siRNA. Knocking down of TLS significantly abolished p42 sumoylation (Figure 2d). Together, these results show that TLS acts as an E3 sumo ligase for p42 and stimulates its sumoylation.

Figure 2
Figure 2

Translocation in liposarcoma (TLS) is a Sumo E3 ligase for Ebp1 p42. (a) TLS associates the sumoylated p42. His-Sumo1 or His-Sumo3 cells were transfected with GST or GST-p42.At 48 h after transfection, cell lysates were pulled down with glutathione beads. The beads were washed extensively and eluted with 10 mM reduced glutathione. The eluted proteins were analysed with silver staining or immunoblotting (IB) with the indicated antibodies. (b) TLS enhances p42 sumoylation. HEK293T cells were transfected with the indicated combinations. At 40 h post transfection, cells were lysed and co-immunoprecipitated with anti-GFP antibody. The samples were subjected to IB with anti-sumo1 antibody. (c) TLS stimulates Ebp1 p42 sumoylation in vitro. Various purified recombinant proteins were incubated with Ebp1 p42 at 37 °C for 2 h. The reaction mixtures were resolved on SDS–PAGE (polyacrylamide gel electrophoresis) and analysed by IB with anti-Ebp1 antibody. (d) TLS knockdown impairs p42 sumoylation. HEK293T cells were transfected with 100 μM of siRNAs directed against TLS or a scrambled siRNA as a negative control. At 24 h post transfection, cells were seeded and transfected with GFP-p42 for an additional 24 h, and then analysed with nickel (Ni2+) column and IB with anti-GFP antibody.

TLS/FUS binds p42 Ebp1

To explore whether the substrate Ebp1 p42 interacts with TLS, we co-transfected GST-p42 and GST-p48 into HEK293 cells with FLAG-TLS. GST pull-down assays showed that both isoforms associated with TLS (Figure 3a, left panels). By contrast, GST control failed to bind TLS (Figure 3a, right panels). To assess whether the interaction occurred between the endogenous proteins, we treated K562 cells with DNA damage agent adriamycin (3 μM) and actinomycin D (10 nM) for different time points and immunoprecipitated Ebp1. Immunoblotting showed that TLS bound to Ebp1 in a time-dependent manner. The binding affinity correlated with Ebp1 sumoylation and S360 phosphorylation status (Figure 3b), indicating that DNA damage regulates the association between Ebp1 and TLS, and subsequently mediates Ebp1 sumoylation, for which Ebp1 S360 phosphorylation might be implicated. Moreover, Ebp1 antibody but not control IgG selectively precipitated TLS from K562 cells in the absence of stimulation, underscoring that endogenous TLS and Ebp1 form a tight complex (Figure 3c). We made similar observations in AU565 cells (data not shown). To investigate the role of Ebp1 phosphorylation in its interaction with TLS, we conducted a co-immunoprecipitation assay with p42 S360D, a phosphorylation mimetic mutant, and S360A, an unphosphorylable mutant. As expected, GST-p42 S360D exhibited a stronger binding affinity to TLS than did wild-type p42, whereas p42 S360A failed to associate with TLS (Figure 3d), supporting that p42 S360 phosphorylation is essential for the TLS/Ebp1 complex formation. Interestingly, p42 S360D showed much stronger sumoylation activity than did wild-type p42 in His-sumo1 stably transfected F293 cells. Co-transfection of TLS further enhanced the effect. In contrast, p42 S360A was barely sumoylated regardless of TLS expression (Figure 3e). Thus, these observations support that p42 phosphorylation promotes its association with TLS and augments its sumoylation.

Figure 3
Figure 3

Translocation in liposarcoma (TLS) interacts with Ebp1 and enhances its sumoylation. (a) P48 and p42 bind TLS. TLS 293T cells were transfected with FLAG-TLS and GST-p42 or with GST-p48 expression vectors, and analysed with glutathione pull-down and immunoblotting (IB) as indicated. (b) Endogenous TLS interacts with Ebp1. Human leukemia K562 cells were treated with genotoxic agents at the indicated concentration for various time points. Endogenous Ebp1 was immunoprecipitated and the associated proteins were analysed by IB with anti-TLS antibody (top panel). Ebp1 was markedly sumoylated and phosphorylated on DNA damage drug treatment (second and third panels). (c) Endogenous Ebp1 and TLS tightly bound to each other even in the absence of drug treatment. The cell lysates (1 mg) were subjected to immunoprecipitation with IgG or anti-Ebp1 antibodies. The immunoprecipitated samples were analysed for anti-TLS antibody. (d) Phosphorylation of Ebp1 increases its binding affinity to TLS. Wild-type p42, S360A and S360D p42 mutants were co-transfected into HEK293 cells with FLAG-TLS. Transfected GST-p42 proteins were pulled down with glutathione beads, and the co-precipitated proteins were analysed by anti-FLAG antibody (top panel). Expression of transfected constructs was verified (middle and bottom panels). (e) Phosphorylation upregulates p42 sumoylation. Wild-type p42, S360A and S360D p42 mutants were co-transfected into F293 cells with or without FLAG-TLS. His-Sumo-modified proteins were pulled down with Ni2+ column, and the co-precipitated proteins were analysed by anti-GST-HRP antibody (top panel). Expression of transfected constructs was verified (middle and bottom panels).

TLS E3 ligase directly binds to Ubc9 and is sumoylated

SUMO E3 ligases, similar to RING domain ubiquitin E3s, do not possess intrinsic enzymatic activity, but act as adapters, which bring together the E2 (Ubc9) and the substrate (Hochstrasser, 2001; Jackson, 2001). To explore whether the TLS E3 ligase indeed interacts with Ubc9, we conducted a GST pull-down assay. The N-terminus of TLS but not its C-terminus interacted with Ubc9 (Figure 4a), agreeing with the in vitro sumoylation results (Figure 4a). TLS also specifically interacted with Ubc9 in the co-transfected HEK293 cells (Figure 4b). To test whether endogenous Ubc9 interacts with TLS, we treated various cells with genotoxic agents and immunoprecipitated Ubc9. Actinomycin D treatment increased the association between Ubc9 and TLS (Figure 4c). We made a similar observation with adriamycin (data not shown). Combined with the finding that Ebp1 also co-precipitated with TLS (Figure 3), these data show that these three proteins (Ebp1/TLS/Ubc9) might form a complex on genotoxic stress. Co-expression of SUMO-1 with FLAG-TLS resulted in the presence of a slower migrating FLAG-reactive band, indicating that TLS may be sumoylated (Figure 4d, left lower panel). Immunoprecipitation with anti-TLS displayed an evidently slower migrating band, suggesting the conjugation of SUMO to TLS (Figure 4d, upper left panel). The co-immunoprecipitation study showed that endogenous SUMO1 also associated with TLS in intact cells (Figure 4d, right panel). Hence, TLS directly binds to the E2 conjugation enzyme Ubc9 and SUMO1, and itself is also sumoylated as well.

Figure 4
Figure 4

Translocation in liposarcoma (TLS) and Ebp1 directly interact with Ubc9. (a) TLS N-terminus is required for its association with Ubc9. Various TLS fragments were co-transfected with GST-Ubc9 into HEK293 cells. Transfected Ubc9 was pulled down by glutathione beads and subjected to immunoblotting (IB) with anti-FLAG antibody. (b) TLS interacts with Ubc9. HEK293T cells were transfected with 5 μg each of FLAG-TLS and T7-Ubc9, and total cell lysates were co-immunoprecipitated with anti-T7 antibody. The immunoprecipitated proteins were subjected to IB with anti-FLAG antibody. (c) Genotoxic stress upregulates the association between TLS and Ubc9. Human leukemic K562 cells were treated with the indicated DNA damage agents for different time points. Endogenous Ubc9 was immunoprecipitated and analysed by IB with anti-TLS antibody. (d) TLS is sumoylated. FLAG-Sumo1 was co-expressed with FLAG-TLS. At 40 h post transfection, cell lysates were immunoprecipitated with anti-TLS antibody and then immunoblotted with anti-Sumo1 antibody (left panel). Endogenous TLS associates with Sumo1. HEK293T cell lysates (1 mg) were subjected to immunoprecipitation with IgG or anti-Sumo1 antibody. The immunoprecipitated proteins were analysed by anti-TLS antibody (right panel).

Ebp1 K93 and K298 residues are sumoylation residues

SUMOylation takes place on lysine residues that are usually embedded within the core consensus motif Ψ-Lys-X-Glu (where Ψ is a hydrophobic amino acid, and X is any amino acid) (Rodriguez et al., 2001). In exploring the sequence of Ebp1, we noticed that amino acids 64–67, FKKE; 92–95, LKSD; 106–109, VKID; and 297–300, AKHE correspond to a motif that is identified as a consensus sumoylation element present in numerous SUMO substrates. To assess the potential sumoylation sites, we co-transfected GFP-Sumo1 into HEK293 cells with various Myc-Ebp1 constructs with K mutated into R. The co-immunoprecipitation assay showed that p42 but not p48 was potently sumoylated, and that the K93R or K298R mutation disrupted Ebp1 sumoylation (Figure 5a). Hence, K93 and K298 residues are major sumoylation sites on Ebp1 p42. To confirm that these two residues are indeed the major sumoylation sites, we co-transfected FLAG-TLS into F293 cells with various p42 constructs. As expected, wild-type p42 was readily sumoylated, and TLS overexpression markedly increased p42 sumoylation. By contrast, none of the K93R, K298R and (K93,298R) mutated proteins were sumoylated even in the presence of TLS (Figure 5b). These results support that K93 and K298 are the major sumoylation sites on Ebp1, and abolishing one residue impairs the other site sumoylation.

Figure 5
Figure 5

P42 is sumoylated at Lysine 93 and 298 residues, required for nucleolar residency. (a) Ebp1 p42 but not p48 isoform can be sumoylated. GFP-Sumo1 was co-transfected into HEK293T cells with various Myc-tagged Ebp1 constructs. Sumoylated proteins were pulled down with anti-GFP antibody and analysed with anti-myc antibody. P42 but not p48 was sumoylated. Either K93R or K298R mutation abolished p42 sumoylation (top panel). Verification of transfected constructs (middle and bottom panels). (b) TLS enhances p42 sumoylation. HEK293T cells were transfected with various indicated expression vectors. At 40 h after transfection, cells were lysed and pulled down with nickel beads. The samples were subjected to immunoblotting (IB) with anti-GFP antibody. Wild-type but not unsumoylated mutants were sumoylated in the presence of TLS (top panel). (cf) Sumoylation is required for p42 nucleolar translocation. HEK293 cells were transfected with the indicated expression vectors, and fixed at 40 h after transfection. Both wild-type and p42 (K93,298R) mutant resided in the cytoplasm, and GFP-Sumo1 exclusively localized in the nucleus and aggregated in the subnuclear compartments (top left panel). Co-transfection of GFP-Sumo1 elicited wild-type p42 but not p42 (K93,298R) mutant nucleolar translocation (middle and bottom left panels). GFP-Sumo1-Ebp1 fusion protein distributed in the nucleus and colocalized with Arf (right panels). The percentage of cells that present the different staining patterns are labeled below each picture. (g) VP16 promotes GFP-p42 wild-type but not S360A nucleolar residency.

p42 predominantly occurs in the cytoplasm, whereas p48 resides in both the cytoplasm and the nucleolus (Liu et al., 2006). Sumoylation frequently triggers protein nuclear translocation. To explore whether p42 sumoylation is required for its nucleolar translocation, we co-transfected GFP-Sumo1 into HEK293 cells with Myc-p42 wild-type and unsumoylated mutant (K93,298R). Immunofluorescent staining showed that Myc-p42 wild-type and unsumoylated mutant alone mainly resided in the cytoplasm, and that co-transfection with Sumo1 provoked wild-type p42 evident nucleolar translocation, whereas unsumoylated mutants predominantly localized in the cytoplasm (Figures 5c and e, left panels). Co-transfection of GFP-Sumo1 elicits p42 nucleolar residency only in a portion of co-transfected HEK293 cells. Sumo fusion protein system has been used for effective production of native proteins (Lee et al., 2008). It has also been used to study the biological functions of sumoylation substrates. For instance, fusion of Sumo1 to the C-terminus but not N-terminus of c-Fos leads to the dramatic stabilization of c-Fos and reduction of its transcriptional activity (Bossis et al., 2005). We found that GFP-Sumo1-p42 recombinant protein exclusively localized in the nuclei of all transfected cells and displayed different subnuclear patterns. Interestingly, some of the transfected GFP-Sumo1-Ebp1 accumulated in the nucleolus, partially colocalizing with Arf (Figures 5d and f), supporting that sumoylation of Ebp1 triggers its nucleolar translocation. These data obtained with artificial fusion protein must be interpreted with caution, because GFP-Sumo1-p42 is localized into some nuclear aggregates that might be just artifacts, because of sumo interaction with other proteins. The nucleolar residency of Ebp1 p42 wild-type but not unsumoylated mutants was further confirmed by immunostaining with nucleolar markers NPM/B23 and Arf in Myc-p42 and GFP-p42 transfected HEK293 cells (Supplementary Figure 1). Unsumoylated mutants were unable to reside in the nucleolus, underscoring that sumoylation is required for p42 nucleolar localization. Moreover, VP16 also provoked wild-type GFP-p42 nucleolar translocation; by contrast, unphosphorylated mutant GFP-p42 S360A remained in the cytoplasm (Figure 5g), indicating that VP16-provoked phosphorylation in p42 is required for its nucleolar translocation. Thus, sumoylation is sufficient and necessary for p42 nucleolar translocation.

Ebp1 sumoylation is required for its anti-proliferative activity

Previous studies have shown that sumoylation might enhance substrate stability. For instance, sumoylation increases HIF-1α (hypoxia-inducible factor-1α) stability and its transcriptional activity (Bae et al., 2004); sumoylation of Oct4 enhances its stability, DNA binding and transactivation (Wei et al., 2007). To explore whether p42 sumoylation also affects its stability, we co-transfected FLAG-Sumo1 into HEK293 cells with GST-p42 wild-type or unsumoylated mutant (K93,298R). The transfected cells were treated with protein translation inhibitor cycloheximide for various time points. In the absence of exogenous SUMO1, wild-type p42 half-life was <6 h, and co-transfection of SUMO1 substantially increased its stability. By contrast, (K93,298R) was almost completely degraded at 6 h regardless of SUMO1 (Figure 6a, left panels), supporting that sumoylation significantly stabilizes p42. NPM/B23 strongly binds Ebp1 (Okada et al., 2007). Depletion of NPM/B23 significantly decreased its half-life even in the presence of Sumo1 (Figure 6a, right panels), supporting that NPM/B23 might stabilize Ebp1 p42. To test whether sumoylation accelerates growth-suppressive activity of p42, we transfected human cancer cells with various constructs and conducted a 5-bromo-2-deoxyuridine (BrdU) incorporation assay. GFP-p42 overexpression resulted in significant cell proliferation decrease, whereas the cell proliferation rate remained similar for both GFP control and GFP-Sumo1. Co-transfection of both Sumo1 and p42 further suppressed cell proliferation, which was comparable with the repressive effect by the recombinant GFP-Sumo1-p42 protein (Figure 6b), supporting that sumoylation of p42 stimulates its growth-suppressive activity.

Figure 6
Figure 6

P42 sumoylation increases its stability and is required for its anti-proliferative activity. (a) Sumoylation is required for the stability of p42. HEK293T cells were transfected with GST-p42 (upper left panel) or unsumoylated GFP-p42 (K93,298R) mutant (lower left panel) and FLAG-Sumo1. Cycloheximide was added to block protein synthesis at various time points before harvesting the cells. Cell lysates were analysed for immunoblotting with anti-GST-HRP antibody or anti-GFP antibody. Depletion of nucleophosmin (NPM)/B23 decreases GST-P42 half-life in the presence of exogenous Sumo1 (right panels). (b) Sumoylation enhances p42 anti-proliferative activity. HEK293 cells were transfected with various constructs and the transfected cells were fed with 5-bromo-2-deoxyuridine (BrdU). Immunostaining showed that co-transfection of p42 and GFP-Sumo1 substantially decreased cell proliferation rate, an effect similar to GFP-Sumo1-p42 recombinant protein overexpression. (left panel) Quantitative analysis of the S-phase in FACS of GFP-Sumo1 and p42 co-transfected cells (right panel). (c) Sumoylation enhances transcriptional suppressive activity of p42. AU565 cells were transfected with the indicated vectors together with E2F1 luciferase reporter gene. At 40 h after transfection, cells were lysed and analysed for luciferase activity. Wild-type p42 repressed E2F-1 transcription activity, and co-transfection of either TLS or Sumo1 further increased its suppressive effect. The maximal effect occurred when both TLS and Sumo1 were co-transfected (left panel). Unsumoylated p42 lost its repressive effect on E2F-1 (right panel). Data are the mean±s.e. for three independent experiments in duplicates. Significant differences were evaluated using Student's t-test (*P<0.01). (d) Colony formation assay. AU565 cells (1 × 104) were seeded into individual wells of six-well plates. p42 and its various sumoylation mutants were transfected into the cells. The number of colonies surviving after 3 weeks of G418 (500 mg/ml) selection was quantified (left panel). Knocking down of TLS increased colony formation and BrdU incorporation assay (right panel). Data are representative for three independent experiments in duplicates.

Ebp1 overexpression inhibits cancer cell proliferation (Zhang et al., 2005; Yu et al., 2007). Ebp1 has been shown to repress various cell-cycle-related gene transcriptions, including cyclin E1 and E2F-1. To examine the effect of sumoylation on transcriptional suppressive activity of Ebp1, we co-transfected E2F-1 luciferase plasmid into HEK293 cells with Ebp1 p42 and (K93,298R) mutant constructs. Compared with the control vector, ectopic expression of p42 decreased luciferase activity by 40%, agreeing with previous observations that overexpression of p42 suppresses cell proliferation. Co-transfection of p42 with either TLS or SUMO1 further enhanced the repressive effect of p42, and the maximal inhibitory effect occurred in TLS, SUMO1 and p42 co-transfected cells. By contrast, transfection of SUMO1 alone or co-transfection of TLS and SUMO1 slightly increased E2F-1 transcription activity (Figure 6c, left panel). Nevertheless, unsumoylated p42 (K93,298R) was unable to suppress the luciferase activity. TLS and SUMO1 lost their stimulatory effects, suggesting that Ebp1 sumoylation is required for its transcription-suppressive activity (Figure 6c, right panel). To further evaluate the effect of sumoylation on the cell growth inhibitory activity of p42, we conducted a colony formation assay with AU565 cells that were stably transfected with wild-type p42 and various unsumoylated mutants. Compared with control, p42 suppressed cancer cell growth. However, K298R mutant failed to inhibit colony formation. Strikingly, p42 K93R and (K93,298R) mutants markedly enhanced cell proliferation (Figure 6d, left panel). Consequently, knocking down of endogenous TLS but not CtBP2, a nuclear transcription co-repressor, selectively increased BrdU incorporation and colony formation (Figure 6d, right panel). These data indicate that abolishing p42 sumoylation somehow facilitates cell proliferation. Together, these results support the notion that sumoylation is required for the anti-proliferative activity of Ebp1 p42.

Discussion

In this study, we identify that TLS/FUS acts as a SUMO E3 ligase for Ebp1 p42. TLS promotes p42 sumoylation at both K93 and K298 residues. Moreover, p42 sumoylation provokes its nucleolar translocation and is required for its stability and repressive activity on E2F-1 transcription factor. Abolishing p42 sumoylation cripples its anti-proliferative activity.

TLS interacts directly with Ubc9, Sumo1 and its substrate Ebp1 p42, and promotes SUMO1 modification of p42, which fulfill all the criteria applicable for an Ebp1 p42 SUMO E3 ligase. TLS might form a multiple protein complex containing sumoylation machinery. Proteomic analysis identified 498 proteins in the purified nucleolar compartment, and TLS is one of them (Andersen et al., 2005). TLS is localized primarily in the nucleus, where it may be involved in pre-mRNA processing and nucleocytoplasmic shuttling, as well as in the regulation of basal transcription (Ron, 1997; Zinszner et al., 1997a). TLS has been proposed to act as a proto-oncogene through chromosomal translocation. N-terminal part of TLS fuses with CHOP in myxoid liposarcoma carrying the t(12;16) translocation (Crozat et al., 1993; Rabbitts et al., 1993), and in different types of human myeloid leukemia in which the C-terminus of TLS is replaced by the DNA-binding domain of ERG (Shimizu et al., 1993; Panagopoulos et al., 1995). BCR/ABL induces increased expression of TLS by preventing its proteasome-dependent degradation (Perrotti et al., 2000). TLS deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death (Hicks et al., 2000). It has been reported that TLS (−/−) mice display male sterility and enhanced radiation sensitivity (Kuroda et al., 2000). All these characteristics resemble another nucleolar protein NPM/B23, which is a ubiquitously expressed nucleolar phosphoprotein that shuttles continuously between the nucleus and the cytoplasm. NPM is translocated or mutated in various lymphomas and leukemias, forming fusion proteins (NPM-ALK, NPM-RARalpha and NPM-MLF1) (Falini et al., 2007). Nonetheless, the role of NPM/B23 in oncogenesis is controversial as it has been attributed to both oncogenic and tumor-suppressive functions. NPM/B23 is essential for embryonic development and the maintenance of genomic stability (Grisendi et al., 2005). Our previous study shows that NPM/B23 binds Ebp1 p42 in the nucleolus, which is regulated by EGF. P42 S360D, a phosphorylation mimetic mutant, strongly binds NPM/B23 (Okada et al., 2007). Interestingly, p42 also strongly binds TLS, which is regulated by DNA damage stress, and Ebp1 phosphorylation increases the interaction (Figure 3). Consistently, immunofluorescent staining with p-Ebp1 S360 antibody shows stronger colocalization by Ebp1 and TLS in the nucleus (Supplementary Figure 2). NPM/B23 is sumoylated on K263 residue, which is essential for NPM/B23 nucleolar residency (Liu et al., 2007). Interestingly, TLS itself is also sumoylated (Figure 4). Conceivably, TLS sumoylation might mediate its nucleolar residency. TLS promotes p42 sumoylation and augments its anti-proliferative activity (Figure 6), indicating that TLS might possess tumor-suppressive activity, although it has been proposed as a proto-oncogene owing to its N-terminal-fused hybrid proteins that possess robust oncogenic effects. Nevertheless, whether wild-type TLS itself possesses any oncogenic activity remains unknown. However, it is worth noting that the knocking down of TLS induces BrdU incorporation (Figure 6d), and this effect might not be exclusively attributed to Ebp1 p42. Nonetheless, p42 suppresses cell proliferation and TLS-promoted sumoylation further enhances its repressive effect. Moreover, the knocking down of TLS diminishes p42 sumoylation. Together, these data indicate that TLS siRNA-induced BrdU incorporation might be, at least in part, regulated by Ebp1 p42.

In this study, we have provided compelling evidence supporting that TLS acts as a physiological E3 sumo ligase for p42. First, TLS binds sumoylation machinery including both SUMO1 and Ubc9 and the substrate p42. Second, overexpression of TLS substantially enhances p42 sumoylation in intact cells and depletion of TLS by siRNA abrogates p42 sumoylation. Third, the in vitro sumoylation assay shows that TLS strongly promotes Ebp1 p42 sumoylation, for which its N-terminus, which binds Ubc9, has an essential role. Hence, our finding establishes that TLS is a new member of the growing list of SUMO E3 ligases.

SUMOylation regulates protein–protein interactions, subcellular localization and stability (Hay, 2001; Muller et al., 2001). Here, we show that p42 Ebp1 sumoylation mediates its association with physiological binding partners. We found that p42 K93R and K298R single mutants decreased their binding affinity to TLS, and that the double mutant K93,298R failed to bind TLS (Supplementary Figure 3). Hence, p42 sumoylation is critical for its association with TLS. Moreover, we also show that sumoylation is essential for its stability. Unsumoylated mutants displayed a shorter half-life than did wild-type proteins (Figure 6a). Many proteins that are important for regulating gene expression, including promoter-specific transcription factors, cofactors and chromatin-modifying enzymes, have been found to be reversibly modified by SUMO. In most cases, SUMOylation of transcriptional regulators correlates with inhibition of transcription (Gill, 2005). Our data support that sumoylation of p42 augments its repressive effect on E2F-1 transcriptional activity, elevating its anti-proliferative activity. On the other hand, abrogating p42 sumoylation cripples its anti-proliferative activity, leading to the upregulation of cancer cell growth and colony formation (Figure 6).

Ebp1 binds NPM/B23 (Okada et al., 2007). Here, we show that Ebp1 p42K298R mutant fails to bind NPM/B23, whereas p42 K93R strongly binds NPM/B23 (Supplementary Figure 4A), suggesting that K298 residue has a critical role in mediating the interaction between p42 and NPM/B23, for which p42 sumoylation might not be essential, because neither K93R nor K298R is sumoylated (Figure 5a). Ebp1 directly interacts with pRB. Overexpression of Ebp1 in MCF-7 and AU565 (Rb(+)) cells inhibits the activity of E2F-1 (Xia et al., 2001). Our previous study shows that wild-type NPM/B23 but not unsumoylated NPM/B23 (K263R) binds Rb. Sumoylated NPM/B23 exhibits robust affinity to pRb (Liu et al., 2007). We found that wild-type p42 upregulates NPM/B23 binding to pRb; in contrast, p42 K298R mutant blocks NPM/B23 binding to pRb (Supplementary Figure 4B), indicating that p42/B23 interaction is indispensable for NPM/B23 interaction with pRb. It has been reported before that DNA-damaging agents, actinomycin D and ultraviolet radiation, induce the dephosphorylation of pRB at Cdk phosphorylation sites and upregulate the binding of pRB to E2F-1, resulting in repression of E2F-1-mediated transcription (Inoue et al., 2007). It can be noted that, genotoxic stress strongly upregulates p42 sumoylation (Figure 1d). Conceivably, DNA damage activates protein kinase Cδ, which phosphorylates p42 and provokes its sumoylation through TLS. The sumoylated p42, in turn, associates with pRB, blocking E2F-1 transcription activity. Collectively, our finding that TLS promotes Ebp1 sumoylation provides a molecular mechanism for post-translational modification mediating Ebp1 transcriptional repressive activity.

Materials and methods

Cells and reagents

His-Sumo stably transfected F293 cells were grown in complete medium containing 1 × Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) containing 10 μg/ml of blasticidin and 100 μg/ml of hygromycin in a humidified incubator at 37 °C, 5% CO2. Expression of the His-SUMO proteins was induced by adding Tet to the culture medium at a final concentration of 1 μg/ml (a generous gift from Dr Van G Wilson, Texas A&M University, College Station, TX, USA). Anti-FLAG monoclonal antibody (M2), anti-hemagglutinin-horseradish peroxide (HA-HRP), anti-Myc and anti-GST-HRP monoclonal antibodies were purchased from Sigma (St Louis, MO, USA); anti-GFP monoclonal antibody was purchased from Roche (Basel, Switzerland). Anti-Ebp1 antibody was purchased from Millipore (Billerica, MA, USA). Anti-Ebp1 S360 has been previously described (Ahn et al., 2006). GFP-Sumo1-Ebp1 construct was prepared by three-step PCR amplification: (1) Sumo 1 was amplified using the following two primers: (a) HindIII Sumo1N 5′-ACTCAAGCTTCATG TCTGACCAGGAGGCAAAACC-3′ and (b) Sumo1Ebp1 (R) 5′-CTGTTTCTTCCATAATCATAACTGTTGAATGACCCCC-3′. (2) Ebp1 was amplified using the following two primers: (c) Sumo1Ebp1 (F) 5′-GGGGGTCATTCAACAGTTATGATTATGGAAGAAACAG-3′ and (d) Kpn1Ebp1 5′-ACTCGGTACCTCAGTCCCCAGCTTCATTTTC-3′. (3) The PCR product from the above two PCRs were mixed and amplified with primers a and d. The resulting fused PCR product was subcloned into p-EGFPC2 vector between HindIII/KpnI sites. All chemicals were purchased from Sigma.

Preparation and transfection of siRNA

The siRNA of TLS was purchased from Dharmacon (Lafayette, CO, USA) (catalog no. M180733-00); The siRNAs were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The sequence for shRNA of NPM/B23 is 5′-GATCCCGAGGAAGATGCAGAGTCAGAAGATGAAGAGAAGCTTGTCTTCATCTTCTGACTCTGCATCTTCCTCTTTTTT-3′. The shRNA subcloned into pGE-1 between BamHI and XbaI, which was then cleaved by XhoI/XbaI and ligated into pAdTrack-CMV for preparing adenovirus.

Co-immunoprecipitation and Nickel column pull-down

Dishes (10 cm) of HEK293 cells were co-transfected with 5 μg of various Myc-p42 constructs and GFP-Sumo1 by Nova Factor. In 24 h, the transfected cells were washed once in phosphate-buffered saline (PBS), lysed in 1 ml lysis buffer (50 mM Tris, pH 7.4, 40 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, 1.5 mM Na3VO4, 50 mM NaF, 10 mM sodium pyrophosphate, 10 mM sodium β-glycerophosphate, 1 mM phenylmethylsulfonyl fluoride, 5 μg/ml aprotinin, 1 μg/ml leupeptin and 1 μg/ml pepstatin A) and centrifuged for 10 min at 14 000 g at 4 °C. After normalizing the protein concentration, 2 μl anti-myc antibody and 40 μl of 50% slurry protein A/G agarose were added to the supernatant and incubated with rotation for 2 h at 4 °C. The agarose pellet was washed three times with 1000 μl lysis buffer each time. The agarose was then resuspended in 30 μl sample buffer separated by SDS–PAGE followed by immunoblotting using anti-GFP antibody. F293 cells were transfected with Myc-42 and induced with Tet for 24 h. His-tagged proteins were pulled down with nickel column. After extensive washing with the above lysis buffer without EDTA, the co-precipitated proteins were analysed by immunoblotting with anti-Myc antibody.

Recombinant protein purification and in vitro SUMOylation assay

Recombinant GST-p42 and His-SUMO1 proteins were expressed in Escherichia coli (BL21). GST-p42 proteins were purified with glutathione-sepharose beads (GE Healthcare, Piscataway, NJ, USA), and His-Sumo1 was purified with Ni2+ column and dialysed against PBS containing 10% glycerol overnight at 4 °C. AOS1 and Ubc9 were from BIOMOL (Plymouth Meeting, PA, USA). All the purified recombinant proteins (TLS and its fragments from mammalian HEK293 cells) were dialysed against PBS containing 10% glycerol. An in vitro SUMOylation analysis of GST-p42 was carried out with the SUMOylation kit (BIOMOL).

Immunofluorescence microscopy

Cells were fixed with either methanol at −20 °C for 20 min or 10% formalin at room temperature for 20 min. The fixed cells were blocked by 10% normal goat serum in PBS for 1 h, and incubated with primary antibodies for 1 h. Cells were then incubated with secondary antibodies (Alexa Fluor 594-tagged goat anti-mouse IgG, Alexa Fluor 488-tagged goat anti-rabbit IgG or Alexa Fluor 594-tagged goat anti-mouse IgG antibodies, Invitrogen) for 1 h and counterstained for DNA with 4′,6-diamidino-2-phenylindole. After incubation with antibodies, cells were washed extensively in PBS. Cells were examined under a fluorescence microscope.

Reporter assays

The E2F-1 promoter-luciferase reporter construct contains a luciferase reporter gene. Cells (1 × 105) in six-well plates were transfected with 0.25 μg of reporter plasmid with various Ebp1 constructs at the indicated concentrations. Renilla thymidine kinase was included as an internal control. After transfection, the cells were placed in complete medium for 48 h. Control or treated cells were harvested to analyse luciferase activity as previously described (Xia et al., 2001).

Colony inhibition assays

AU565 cells (1 × 104) were seeded into individual wells of six-well plates. Ebp1 plasmid DNA (2 μg) was stably transfected using Fugene 6 Roche. The number of colonies surviving after 3 weeks of G418 (500 μg/ml) selection was determined microscopically.

BrdU incorporation assay

Cells were seeded into six-well plates at 1 × 105 cells per well, cultured overnight and transfected with various siRNA. The transfected cells were pulse labeled with BrdU (10 μm; GE Healthcare). The incorporation was continued for 10 min. After washing with cold PBS, the cells were fixed with 4% paraformaldehyde for 15 min and treated with 2 M HCl at 37 °C for 30 min. The coverslips were blocked with 2% FBS/PBS and 0.4% Triton X-100 for 10 min at room temperature. For immunostaining, mouse monoclonal antibody against BrdU (1:200) and anti-GST-FITC-conjugated antibody were used.

Conflict of interest

The authors declare no conflict of interest.

References

  1. , , , , , et al. (2006). Nuclear Akt associates with PKC-phosphorylated Ebp1, preventing DNA fragmentation by inhibition of caspase-activated DNase. EMBO J 25: 2083–2095.

  2. , , , , , et al. (1996). Expression patterns of the human sarcoma-associated genes FUS and EWS and the genomic structure of FUS. Genomics 37: 1–8.

  3. , , , , , et al. (2005). Nucleolar proteome dynamics. Nature 433: 77–83.

  4. , , , , , et al. (2004). Sumoylation increases HIF-1alpha stability and its transcriptional activity. Biochem Biophys Res Commun 324: 394–400.

  5. , , , , , et al. (2005). Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation. Mol Cell Biol 25: 6964–6979.

  6. , , , . (1993). Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 363: 640–644.

  7. , , , , , et al. (2007). Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica 92: 519–532.

  8. . (2005). Something about SUMO inhibits transcription. Curr Opin Genet Dev 15: 536–541.

  9. , , , , , et al. (2005). Role of nucleophosmin in embryonic development and tumorigenesis. Nature 437: 147–153.

  10. . (2001). Protein modification by SUMO. Trends Biochem Sci 26: 332–333.

  11. , , , , , et al. (2000). Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death. Nat Genet 24: 175–179.

  12. . (2001). SP-RING for SUMO: new functions bloom for a ubiquitin-like protein. Cell 107: 5–8.

  13. , . (2008). The DNA damage response pathways: at the crossroad of protein modifications. Cell Res 18: 8–16.

  14. , , . (2007). Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB and E2F-1 after DNA damage. EMBO J 26: 2083–2093.

  15. . (2001). A new RING for SUMO: wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases. Genes Dev 15: 3053–3058.

  16. , , , , , . (1997). Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein. Am J Pathol 151: 735–744.

  17. , , , , , et al. (2000). Male sterility and enhanced radiation sensitivity in TLS(−/−) mice. EMBO J 19: 453–462.

  18. , , , , , et al. (2008). An improved SUMO fusion protein system for effective production of native proteins. Protein Sci 17: 1241–1248.

  19. , , , , , et al. (2007). Sumoylation of nucleophosmin/B23 regulates its subcellular localization, mediating cell proliferation and survival. Proc Natl Acad Sci USA 104: 9679–9684.

  20. , , , . (2006). Ebp1 isoforms distinctively regulate cell survival and differentiation. Proc Natl Acad Sci USA 103: 10917–10922.

  21. . (1998). Multisite phosphorylation and the integration of stress signals at p53. Cell Signal 10: 159–166.

  22. , , , , , et al. (1998). Genomic structure of the human RBP56/hTAFII68 and FUS/TLS genes. Gene 221: 191–198.

  23. , , , . (2001). SUMO, ubiquitin's mysterious cousin. Nat Rev Mol Cell Biol 2: 202–210.

  24. , , , , . (1997). Tissue distribution and subcellular localization of rabbit liver metalloendopeptidase. J Histochem Cytochem 45: 41–47.

  25. , , . (2007). Ebp1 association with nucleophosmin/B23 is essential for regulating cell proliferation and suppressing apoptosis. J Biol Chem 282: 36744–36754.

  26. , , , . (1995). Two distinct FUS breakpoint clusters in myxoid liposarcoma and acute myeloid leukemia with the translocations t(12;16) and t(16;21). Oncogene 11: 1133–1137.

  27. , , , , , et al. (2000). BCR-ABL prevents c-jun-mediated and proteasome-dependent FUS (TLS) proteolysis through a protein kinase CbetaII-dependent pathway. Mol Cell Biol 20: 6159–6169.

  28. , , , , . (1994). TLS/FUS fusion domain of TLS/FUS-erg chimeric protein resulting from the t(16;21) chromosomal translocation in human myeloid leukemia functions as a transcriptional activation domain. Oncogene 9: 3717–3729.

  29. , , , . (1993). Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 4: 175–180.

  30. , . (1995). Molecular cloning of a murine cDNA encoding a novel protein, p38-2G4, which varies with the cell cycle. Exp Cell Res 220: 434–445.

  31. , , . (2001). SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J Biol Chem 276: 12654–12659.

  32. . (1997). TLS-CHOP and the role of RNA-binding proteins in oncogenic transformation. Curr Top Microbiol Immunol 220: 131–142.

  33. , . (1994). Transcriptional activation by TAL1 and FUS-CHOP proteins expressed in acute malignancies as a result of chromosomal abnormalities. Proc Natl Acad Sci USA 91: 7869–7873.

  34. , , , . (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325–334.

  35. , , , , , et al. (1993). An ets-related gene, ERG, is rearranged in human myeloid leukemia with t(16;21) chromosomal translocation. Proc Natl Acad Sci USA 90: 10280–10284.

  36. , , , , . (2004). EBP1 is a nucleolar growth-regulating protein that is part of pre-ribosomal ribonucleoprotein complexes. Oncogene 23: 4454–4465.

  37. . (2006). Sumoylation of PCNA: wrestling with recombination at stalled replication forks. DNA Repair (Amst) 5: 399–403.

  38. , , . (2007). Sumoylation of Oct4 enhances its stability, DNA binding, and transactivation. J Biol Chem 282: 21551–21560.

  39. , , , , . (2001). Ebp1, an ErbB-3 binding protein, interacts with Rb and affects Rb transcriptional regulation. J Cell Physiol 187: 209–217.

  40. , , , , , et al. (2000). Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin. Br J Cancer 82: 683–690.

  41. , , , , , . (2007). Suppression of salivary adenoid cystic carcinoma growth and metastasis by ErbB3 binding protein Ebp1 gene transfer. Int J Cancer 120: 1909–1913.

  42. , , , , , et al. (2005). The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. Proc Natl Acad Sci USA 102: 9890–9895.

  43. , , , . (2003). Repression of E2F1-mediated transcription by the ErbB3 binding protein Ebp1 involves histone deacetylases. Nucleic Acids Res 31: 2168–2177.

  44. , , . (1994). A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev 8: 2513–2526.

  45. , , , , . (1997a). A topogenic role for the oncogenic N-terminus of TLS: nucleolar localization when transcription is inhibited. Oncogene 14: 451–461.

  46. , , , , . (1997b). TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J Cell Sci 110(Part 15): 1741–1750.

Download references

Acknowledgements

This work is supported by grants from the National Institute of Health (RO1, CA127119) to K Ye. We thank Dr Yang Liu at Medical Research Service (VA Puget Sound Health Care System, Seattle, WA, USA) for TLS constructs.

Author information

Affiliations

  1. Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA

    • S-M Oh
    • , Z Liu
    • , M Okada
    • , S-W Jang
    • , X Liu
    • , C-B Chan
    •  & K Ye
  2. Department of Pathology and Lab Medicine, Harvard Medical School and Children's Hospital Boston, Boston, MA, USA

    • H Luo

Authors

  1. Search for S-M Oh in:

  2. Search for Z Liu in:

  3. Search for M Okada in:

  4. Search for S-W Jang in:

  5. Search for X Liu in:

  6. Search for C-B Chan in:

  7. Search for H Luo in:

  8. Search for K Ye in:

Corresponding author

Correspondence to K Ye.

Supplementary information

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/onc.2009.411

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)

Further reading